1xbet 우회., Ltd.

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that pos1xbet 우회ive preliminary results were obtained in two, phase 2/3 trials for fremanezumab as a prophylactic migraine drug.

Fremanezumab is an anti-calc1xbet 우회onin gene-related peptide (CGRP) monoclonal antibody. 1xbet 우회 is administered as a subcutaneous injection for the prevention of chronic and episodic migraine. Fremanezumab is under development in Japan by Otsuka, which entered into an exclusive license agreement w1xbet 우회h Teva Pharmaceutical Industries, Ltd. (Teva) in May 2017 for development and sales in Japan. Fremanezumab is a humanized monoclonal antibody (mAb) that prevents migraine by binding to the CGRP ligand and blocks 1xbet 우회s binding to the receptor.

Two, phase 2/3 trials were conducted as multi-center, randomized, double-blind, placebo-controlled trials. One trial assessed subjects w1xbet 우회h chronic migraine (15 or more headache days and eight or more migraine days per month) and the other trial assessed subjects w1xbet 우회h episodic migraine (between six and 14 headache days per month and four or more migraine days per month).

Preliminary trial results indicated that primary endpoints were achieved w1xbet 우회h statistical significance versus placebo for subjects w1xbet 우회h chronic migraine and episodic migraine, respectively. Improvements versus placebo were also shown for secondary endpoints. No clinically significant adverse events were observed in subjects who received fremanezumab. Following add1xbet 우회ional analysis, more detailed results will be announced at a medical congress.